drugset / Trial / NCT05895123

Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients

NCT05895123

RandomizedParallel-groupSingle-blindTreatment

Summary

STEMI is a serious type of coronary heart disease, which is a major cause of disability and death. Morphologically the key feature of remodeling is myocyte hypertrophy, myocyte loss from necrosis or apoptosis, as well as interstitial cell growth especially fibroblast proliferation leading to myocardial fibrosis . Elevated serum LDL-cholesterol concentrations play a proatherogenic role by stimulating inflammation and oxidative processes. Statins have been documented to retard fibrosis and ventricular hypertrophy by the cessation of myofibroblast activity. Clinical studies have proven that statins not only regulate lipids but also improve myocardial fibrosis, regulate cell proliferation and apoptosis, regulate ventricular remodeling, and protect the myocardium

Timeline

Start
2021-11-01
Primary completion
2023-03-01
Completion
2023-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 40 mg Oral
Subject Rosuvastatin Small molecule 20 mg Oral